In a move to solidify its leadership in the attention-deficit/hyperactivity disorder (ADHD) market, Massachusetts-based Collegium Pharmaceutical has struck a deal to acquire the drug Azstarys from Corium Therapeutics. The transaction carries a total potential value of nearly $800 million.
Deal details and market outlook:
-
Financial structure: Collegium will pay $650 million upfront in cash, with an additional $135 million in potential milestone payments based on future regulatory and sales targets.
-
Exclusive product advantages: Azstarys is the first and only ADHD treatment to combine both immediate-release and long-acting components in a single capsule. The product is expected to maintain market exclusivity until 2037.
-
Portfolio diversification strategy: The addition of Azstarys gives Collegium a complementary duo of ADHD medications: while Jornay PM (acquired in 2024) is taken at bedtime for morning efficacy, Azstarys is taken in the morning for rapid onset and all-day coverage.
-
Revenue expectations: Collegium projects that Azstarys will generate over $50 million in revenue in the second half of 2026 alone. This is a critical step in helping the company diversify away from its traditional pain management portfolio.
The deal is expected to close in the second quarter of this year, marking Collegium’s significant pivot toward specialized central nervous system (CNS) treatments.
Source: https://www.fiercepharma.com/pharma/collegium-ponies-650m-gain-adhd-drug-azstarys-corium